{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:54:18Z","timestamp":1792896858345,"version":"4.5.0"},"reference-count":23,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014688","name":"Region Uppsala","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: Mastocytosis is a disease characterized by accumulation of aberrant mast cells and mediator-related symptoms and is divided into systemic mastocytosis (SM) and cutaneous mastocytosis (CM). The epidemiology of mastocytosis remains incompletely understood.\nObjective: To estimate the incidence, prevalence, overall survival (OS) and burden of comorbidities in adult mastocytosis patients identified in Swedish population-based registries.\nMethods: Individuals (\u2265 20 years of age) with a mastocytosis diagnosis in the National Patient Register (NPR) and\/or the Swedish Cancer Register (SCR) between 2001 and 2018, were identified. In a matched cohort design, for each case five randomly selected mastocytosis-free comparators matched on age, sex, and county of residence were chosen from the Population Register. The Kaplan-Meier method was used to compare OS between individuals with mastocytosis and comparators. Information on concomitant disease at baseline was assessed by use of the Charlson Comorbidity Index (CCI).\nResults: We identified 2,040 adults with a mastocytosis diagnosis yielding an annual incidence of 1.56 per 100,000 (95% CI 1.29\u20131.87) and a prevalence of 23.9 per 100,000 (95% CI 22.8\u201325.0). The comorbidity burden was higher, and the OS lower, in patients with mastocytosis compared to comparators.\nInterpretation: We found a higher incidence and prevalence of mastocytosis compared to assessments in other settings and confirmed that the prognosis generally is favorable. Of special note was evidence of a higher comorbidity burden in mastocytosis patients compared to the background population.\nLimitations: Underreporting and inconsistencies in the use of diagnostic codes.<\/jats:p>","DOI":"10.2340\/1651-226x.2024.31406","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:10:55Z","timestamp":1708503055000},"page":"44-50","source":"Crossref","is-referenced-by-count":33,"title":["Epidemiology of mastocytosis: a population-based study (Sweden)"],"prefix":"10.2340","volume":"63","author":[{"given":"Anna","family":"Bergstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"H\u00e4gglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"49554","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5:11. https:\/\/doi.org\/10.1097\/HS9.0000000000000646","DOI":"10.1097\/HS9.0000000000000646"},{"key":"49555","doi-asserted-by":"crossref","unstructured":"Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112:946\u201356. https:\/\/doi.org\/10.1182\/blood-2007-11-078097","DOI":"10.1182\/blood-2007-11-078097"},{"key":"49556","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420\u20137. https:\/\/doi.org\/10.1182\/blood-2016-09-731893","DOI":"10.1182\/blood-2016-09-731893"},{"key":"49557","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","DOI":"10.1038\/s41375-022-01613-1"},{"key":"49558","doi-asserted-by":"crossref","unstructured":"Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35\u201345. https:\/\/doi.org\/10.1016\/j.jaci.2015.08.034","DOI":"10.1016\/j.jaci.2015.08.034"},{"key":"49559","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435\u201353. https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01807.x","DOI":"10.1111\/j.1365-2362.2007.01807.x"},{"key":"49560","doi-asserted-by":"crossref","unstructured":"Berezowska S, Flaig MJ, Ru\u00ebff F, et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol Off J U S Can Acad Pathol Inc. 2014; 27: 19\u201329. https:\/\/doi.org\/10.1038\/modpathol.2013.117","DOI":"10.1038\/modpathol.2013.117"},{"key":"49561","doi-asserted-by":"crossref","unstructured":"van Doormaal JJ, Arends S, Brunekreeft KL, van der Wal VB, et al. Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol. 2013;131:1429\u201331. https:\/\/doi.org\/10.1016\/j.jaci.2012.10.015","DOI":"10.1016\/j.jaci.2012.10.015"},{"key":"49562","doi-asserted-by":"crossref","unstructured":"Cohen SS, Skovbo S, Vestergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166:521\u20138. https:\/\/doi.org\/10.1111\/bjh.12916","DOI":"10.1111\/bjh.12916"},{"key":"49563","doi-asserted-by":"crossref","unstructured":"Kibsgaard L, Deleuran M, Flohr C, Langan S, Braae Olesen A, Verstergaard C. How \u2018benign\u2019 is cutaneous mastocytosis? A Danish registry-based matched cohort study. Int J Womens Dermatol. 2020;6:294\u2013300. https:\/\/doi.org\/10.1016\/j.ijwd.2020.05.013","DOI":"10.1016\/j.ijwd.2020.05.013"},{"key":"49564","doi-asserted-by":"crossref","unstructured":"Zanotti R, Bonifacio M, Isolan C, et al. A multidisciplinary diagnostic approach reveals a higher prevalence of indolent systemic mastocytosis: 15-years\u2019 experience of the GISM network. Cancers. 2021;13:6380. https:\/\/doi.org\/10.3390\/cancers13246380","DOI":"10.3390\/cancers13246380"},{"key":"49565","doi-asserted-by":"crossref","unstructured":"Ungerstedt J, Ljung C, Klimkowska M, G\u00fclen T. Clinical outcomes of adults with systemic mastocytosis: a 15-year multidisciplinary experience. Cancers. 2022;14:3942. https:\/\/doi.org\/10.3390\/cancers14163942","DOI":"10.3390\/cancers14163942"},{"key":"49566","doi-asserted-by":"crossref","unstructured":"G\u00fclen T, Akin C. Anaphylaxis and mast cell disorders. Immunol Allergy Clin North Am. 2022;42:45\u201363. https:\/\/doi.org\/10.1016\/j.iac.2021.09.007","DOI":"10.1016\/j.iac.2021.09.007"},{"key":"49567","doi-asserted-by":"crossref","unstructured":"Greene LW, Asadipooya K, Corradi PF, Akin C. Endocrine manifestations of systemic mastocytosis in bone. Rev Endocr Metab Disord. 2016;17:419\u201331. https:\/\/doi.org\/10.1007\/s11154-016-9362-3","DOI":"10.1007\/s11154-016-9362-3"},{"key":"49568","doi-asserted-by":"crossref","unstructured":"H\u00e4gglund H, Sander B, G\u00fclen T, Lindel\u00f6f B, Nilsson G. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol. 2014; 94: 583\u2013584. https:\/\/doi.org\/10.2340\/00015555-1788","DOI":"10.2340\/00015555-1788"},{"key":"49569","doi-asserted-by":"crossref","unstructured":"Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study. Am J Hematol. 2016;91:1069\u201375. https:\/\/doi.org\/10.1002\/ajh.24490","DOI":"10.1002\/ajh.24490"},{"key":"49570","doi-asserted-by":"crossref","unstructured":"Indhirajanti S, van Daele PLA, Bos S, Mulder MT, Bot I, Roeters van Lennep JE. Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels. Atherosclerosis. 2018;268:152\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.030","DOI":"10.1016\/j.atherosclerosis.2017.11.030"},{"key":"49571","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"49572","doi-asserted-by":"crossref","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382. https:\/\/doi.org\/10.1093\/aje\/kwq433","DOI":"10.1093\/aje\/kwq433"},{"key":"49573","doi-asserted-by":"crossref","unstructured":"Valent P, Hartmann K, Bonadonna P, et al. European Competence Network on Mastocytosis (ECNM): 20-year Jubilee, updates, and future perspectives. J Allergy Clin Immunol Pract. 2023;11(6):1706\u20131717. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.021","DOI":"10.1016\/j.jaip.2023.02.021"},{"key":"49574","doi-asserted-by":"crossref","unstructured":"Lim K-H, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009; 113: 5727\u201336. https:\/\/doi.org\/10.1182\/blood-2009-02-205237","DOI":"10.1182\/blood-2009-02-205237"},{"key":"49575","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Gleixner KV, et al. Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches. Int J Mol Sci. 2019;20(12):2976. https:\/\/doi.org\/10.3390\/ijms20122976","DOI":"10.3390\/ijms20122976"},{"key":"49576","doi-asserted-by":"crossref","unstructured":"Broesby-Olsen S, Dybedal I, G\u00fclen T, et al. Multidisciplinary management of mastocytosis: Nordic Expert Group consensus. Acta Derm Venereol. 2016;96:602\u201312. https:\/\/doi.org\/10.2340\/00015555-2325","DOI":"10.2340\/00015555-2325"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/31406\/45399","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/31406\/45399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:06:00Z","timestamp":1756404360000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/31406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2024.31406","relation":{},"ISSN":["1651-226X","0284-186X"],"issn-type":[{"value":"1651-226X","type":"electronic"},{"value":"0284-186X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}